These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36869230)

  • 1. Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features.
    Esteves-Ferreira S; Rosinha P
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7925-7932. PubMed ID: 36869230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.
    Joshi MN; Whitelaw BC; Palomar MT; Wu Y; Carroll PV
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):331-9. PubMed ID: 26998595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
    Fernandes S; Varlamov EV; McCartney S; Fleseriu M
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitor-related hypophysitis.
    Mizukoshi T; Fukuoka H; Takahashi Y
    Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101668. PubMed ID: 35562229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor therapy-induced hypophysitis ∼ a case series of Taiwanese patients.
    Lin CH; Chen KH; Chen KY; Shih SR; Lu JY
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):524-529. PubMed ID: 30104119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review.
    Oğuz SH; Ünlütürk U; Aksoy S; Erbas T
    Immunotherapy; 2021 Oct; 13(14):1157-1163. PubMed ID: 34387129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary and adrenal disorders induced by immune checkpoint inhibitors.
    Albarel F; Brue T; Castinetti F
    Ann Endocrinol (Paris); 2023 May; 84(3):339-345. PubMed ID: 36965852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Checkpoint inhibitors-induced hypophysitis].
    du Payrat JA; Cugnet-Anceau C; Maillet D; Levy M; Raverot G; Disse E; Borson-Chazot F
    Bull Cancer; 2020 Apr; 107(4):490-498. PubMed ID: 32200950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
    Vazquez A
    Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
    Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
    J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy.
    Atkinson M; Lansdown AJ
    Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101635. PubMed ID: 35382989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary-related immune adverse events induced by programmed death Protein-1 inhibitors differ clinically from hypophysitis.
    Yang L; Zhang Y; Chen X; Liu K; Zhou Y; Wang S
    Clin Endocrinol (Oxf); 2024 Aug; 101(2):130-139. PubMed ID: 38753540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis.
    Kurokawa R; Ota Y; Gonoi W; Hagiwara A; Kurokawa M; Mori H; Maeda E; Amemiya S; Usui Y; Sato N; Nakata Y; Moritani T; Abe O
    AJNR Am J Neuroradiol; 2020 Sep; 41(9):1683-1689. PubMed ID: 32763900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature.
    Newman C; Kgosidalwa O; Hakami OA; Kennedy C; Grogan L; Agha A
    BMC Endocr Disord; 2021 Feb; 21(1):33. PubMed ID: 33639911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How we treat endocrine complications of immune checkpoint inhibitors.
    Paschou SA; Stefanaki K; Psaltopoulou T; Liontos M; Koutsoukos K; Zagouri F; Lambrinoudaki I; Dimopoulos MA
    ESMO Open; 2021 Feb; 6(1):100011. PubMed ID: 33399077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer: A Case Report.
    Li R; Jiang B; Zhu Y; Gao L; Zhou Y; Yang S
    Endocr Metab Immune Disord Drug Targets; 2024; 24(5):606-610. PubMed ID: 37818555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine dysfunction induced by immune checkpoint inhibitors.
    Deligiannis NG; Sosa S; Danilowicz K; Rizzo LFL
    Medicina (B Aires); 2021; 81(2):269-278. PubMed ID: 33906146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring a Rarity: Incidence of and Therapeutic Approaches for Neurological Complications and Hypophysitis in Cancer Patients on Immune Checkpoint Inhibitors-A Single-Center Study.
    Amylidi AL; Gogadis A; Yerolatsite M; Zarkavelis G; Torounidou N; Keramisanou V; Kampletsas E; Mauri D
    Curr Oncol; 2023 Dec; 30(12):10509-10518. PubMed ID: 38132400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid disorders induced by checkpoint inhibitors.
    Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
    Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.